Millennium Management
ALXN

Millennium Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Millennium Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,829,380
Closed -$887M – 7630
2021
Q2 		$887M Buy
4,829,380
+2,276,841
+89% +$391M 0.54% 21
2021
Q1 		$390M Buy
2,552,539
+668,892
+36% +$103M 0.28% 36
2020
Q4 		$294M Buy
1,883,647
+1,641,582
+678% +$211M 0.21% 59
2020
Q3 		$27.7K Sell
242,065
-136,878
-36% -$14.8M 0.03% 607
2020
Q2 		$42.5M Sell
378,943
-405,380
-52% -$43M 0.06% 346
2020
Q1 		$70.4M Buy
784,323
+641,975
+451% +$63M 0.16% 106
2019
Q4 		$15.4M Sell
142,348
-273,213
-66% -$29.2M 0.02% 1016
2019
Q3 		$40.7M Buy
415,561
+163,892
+65% +$18.5M 0.06% 389
2019
Q2 		$33M Buy
251,669
+130,342
+107% +$16.8M 0.05% 518
2019
Q1 		$16.4M Sell
121,327
-536,489
-82% -$66.7M 0.02% 921
2018
Q4 		$64M Buy
+657,816
New +$77.8M 0.1% 261
2018
Q3 		– Sell
-206,242
Closed -$25.9M – 4440
2018
Q2 		$25.6M Sell
206,242
-724,889
-78% -$84.7M 0.03% 728
2018
Q1 		$104M Buy
931,131
+894,437
+2,438% +$107M 0.14% 174
2017
Q4 		$4.39M Sell
36,694
-227,394
-86% -$27.7M 0.01% 1803
2017
Q3 		$37M Sell
264,088
-189,659
-42% -$25.8M 0.06% 457
2017
Q2 		$55.2M Sell
453,747
-407,173
-47% -$47.4M 0.1% 274
2017
Q1 		$104M Buy
860,920
+631,609
+275% +$81.4M 0.19% 113
2016
Q4 		$28.1M Sell
229,311
-775,087
-77% -$94.8M 0.06% 461
2016
Q3 		$123M Buy
1,004,398
+85,454
+9% +$11M 0.21% 66
2016
Q2 		$107M Buy
918,944
+372,875
+68% +$52.9M 0.25% 67
2016
Q1 		$76M Buy
546,069
+523,924
+2,366% +$76.9M 0.19% 102
2015
Q4 		$4.22M Sell
22,145
-14,566
-40% -$2.54M 0.01% 1475
2015
Q3 		$5.74M Sell
36,711
-1,255,262
-97% -$229M 0.01% 1254
2015
Q2 		$234M Buy
1,291,973
+388,617
+43% +$67.1M 0.44% 20
2015
Q1 		$157M Buy
903,356
+563,534
+166% +$102M 0.29% 45
2014
Q4 		$62.9M Buy
339,822
+137,656
+68% +$25.5M 0.13% 160
2014
Q3 		$33.5M Sell
202,166
-725,534
-78% -$119M 0.08% 280
2014
Q2 		$145M Sell
927,700
-49,838
-5% -$7.87M 0.4% 25
2014
Q1 		$149M Buy
977,538
+115,748
+13% +$18.4M 0.43% 18
2013
Q4 		$115M Buy
861,790
+502,267
+140% +$60.3M 0.36% 24
2013
Q3 		$41.8M Sell
359,523
-227,212
-39% -$24.9M 0.13% 114
2013
Q2 		$54.1M Buy
+586,735
New +$56.5M 0.17% 67

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Millennium Management's ALXN Position: Q3 2021 in Review

Millennium Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,829,380 shares — an estimated $887M sold.

Millennium Management first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $887M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Millennium Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Millennium Management sold 4,829,380 Alexion Pharmaceuticals shares in Q3 2021, an estimated $887M.
  • Millennium Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • Millennium Management's Alexion Pharmaceuticals position peaked at $887M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.